🇺🇸 Somatostatin analog in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Abdominal Pain — 3 reports (21.43%)
  2. Flatulence — 2 reports (14.29%)
  3. Nausea — 2 reports (14.29%)
  4. 5-Hydroxyindolacetic Acid Increased — 1 report (7.14%)
  5. Alopecia — 1 report (7.14%)
  6. Anxiety — 1 report (7.14%)
  7. Asthenia — 1 report (7.14%)
  8. Blood Potassium Decreased — 1 report (7.14%)
  9. Defaecation Urgency — 1 report (7.14%)
  10. Diarrhoea — 1 report (7.14%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Somatostatin analog approved in United States?

Somatostatin analog does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Somatostatin analog in United States?

The Netherlands Cancer Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.